Stock Yearly Return 2015
Start date: 12/31/2014
End date: 12/31/2015
Start price/share: $20.76
End price/share: $68.11
Dividends collected/share: $0.00
Total return: 228.08%
Average Annual Total Return: 228.08%
Starting investment: $10,000.00
Ending investment: $32,808.00
Years: 1.00


PRTA average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare PRTA average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into PRTA


Also see:
PRTA stock yearly return 2016
PRTA stock yearly return 2017
PRTA stock yearly return 2018
PRTA stock yearly return 2019
PRTA stock yearly return 2020
PRTA YTD return
PRTA average annual return 10 years
Prothena is a clinical-stage neuroscience company. Co. is developing a pipeline of therapeutic candidates for a number of indications and targets. Co.'s partnered programs include prasinezumab (PRX002/RG7935) for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target for the potential treatment of Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia or other neurodegenerative diseases. Co.'s proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target Amyloid beta for the potential treatment of Alzheimer's disease. The PRTA stock yearly return is shown above.

The yearly return on the PRTA stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2015 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the PRTA annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for PRTA:
PRTA SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Prothena (PRTA) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

PRTK Average Annual Return
PRTO Average Annual Return
PSTI Average Annual Return
PTCT Average Annual Return
PTGX Average Annual Return
PTI Average Annual Return
PTIE Average Annual Return
PTLA Average Annual Return
PTX Average Annual Return
PULM Average Annual Return
More Healthcare companies »

 

PRTA Stock Yearly Return 2015 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.